Poster (download)
239
Vitaly Omelchenko1, Elena Letyagina2, Alla Shevchenko3, Yuliya Kurochkina4, Anna Akimova5, Maxim Korolev6
1Research Institute of Clinical and Experimental LymСЂhology – Branch of the Institute of Cytology and Genetics, v.o.omelchenko@gmail.com
2Research Institute of Clinical and Experimental LymСЂhology – Branch of the Institute of Cytology and Genetics, elena_letyagina@list.ru
3Research Institute of Clinical and Experimental LymСЂhology – Branch of the Institute of Cytology and Genetics, shalla64@mail.ru
4Research Institute of Clinical and Experimental LymСЂhology – Branch of the Institute of Cytology and Genetics, juli_k@bk.ru
5Research Institute of Clinical and Experimental LymСЂhology – Branch of the Institute of Cytology and Genetics, calor844@gmail.com
6Research Institute of Clinical and Experimental LymСЂhology – Branch of the Institute of Cytology and Genetics, kormax@bk.ru
Objectives: The aim of our study was to analyze the association between some SNPs and treatment of rheumatoid arthritis with biological drugs.
Patients and methods: We studied 368 Russian patients with rheumatoid arthritis. All of them were treated in accordance with the standard recommendations. Fifty seven patient received biological disease-modifying antirheumatic drugs. Single nucleotide polymorphisms (TNFО± C-863A, TNFО± G-308A, TNFО± G-238A, IL1ОІ T-31РЎ, IL4 РЎ-590T, IL6 G-174C, IL10 A-1082G, IL10 РЎ-592Рђ, VEGFA C+936T, VEGFA C-2578A) were determined by restriction fragment length polymorphism analysis of PCR-amplified fragments (PCR-RFLP) or RT-PCR.
Results: The IL1β T-31C and VEGFA C+936T SNPs were association with bDMARDs treatment. Homozygotes IL1b -31CC and VEGFА +936 CC were more frequently in bDMARDs group compare with patients without bDMARDs (28.1% vs 17.1%, p=0.044 and 80.4% vs 66.6%, p=0.041). Other polymorphisms didn’t demonstrate any significant differences.
Conclusions: Our data suggest, that IL1ОІ T-31C and VEGFA C+936T SNPs can be used as part of a comprehensive assessment of the prognosis of the treatment effectiveness.
What do you mean by DOMINANT in the case “dominant homozygotes VEGFА +936 CC“ ?